Xanomeline is a drug used to treat Alzheimer's disease and schizophrenia, but it may contain impurities that affect its purity and efficacy. Xanomeline impurities are unwanted substances that can be generated during the manufacturing process or storage. These impurities can affect the quality, safety, and efficacy of the drug. Therefore, it is essential to monitor and control the levels of these impurities to ensure that the drug is safe and effective for patients.
